Ardea Biosciences — Corporate Update (November 2009)
34 slides from Ardea Biosciences's corporate update, Nov 3, 2009
Slide 1: Company Update November 3, 2009
Company Update November 3, 2009
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Status of Development Programs
Status of Development Programs RDEA427 RDEA806 900 Series Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer 3 Gout RDEA594 RDEA684 MEKI + sorafenib for cancer RDEA119 Gout Partnered with Bayer RDEA119 3rd Gen NNRTIs
Slide 4: Gout/Hyperuricemia
Gout/Hyperuricemia Ardea) Biosciences
Slide 5: Hyperuricemia/Gout - Unmet Medical Need
Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease Attacks of severe pain/Inflammation Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (> 5,000,000 potential
Slide 6: Uric Acid Production and Elimination
Hare, J. M. et al. Circulation 2003;107:1951-1953 Uric Acid Production and Elimination Allopurinol Febuxostat RDEA594 Probenecid Losartan (Cozaar(r)) Benzbromarone* 6 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Pegloticase URAT1
Slide 7: Selective URAT1 Transporter Inhibition: An Important Contribution to Treatment
7 Selective URAT1 Transporter Inhibition: An Important Contribution to the Treatment of Hyperuricemia/Gout Inhibition of the URAT1 transporter is a well-validated target for gout Benzbromarone has over 10 million patient-years of treatment experience, with very few side effects, except liver toxicit
Slide 8: Uric Acid-Lowering Was Noticed With RDEA806
Uric Acid-Lowering Was Noticed With RDEA806 Up to 45% reductions in serum urate (sUA) were observed in healthy volunteers in the 10-day multiple ascending dose study Uric acid reductions of were also observed in all HIV patients in the Phase 2a monotherapy study with RDEA806 A 28-day proof-of-concep
Slide 9: RDEA594 Preclinical and Phase 1 Summary
RDEA594 Preclinical and Phase 1 Summary RDEA594 is a selective inhibitor of the URAT1 renal transporter (EC50 = 5-10 ^M) without antiviral activity No effect on OAT1 and OAT3 transporters (no interaction with antivirals or other drugs secreted by these transporters) Limited metabolism by CYP450 Inhi
Slide 10: RDEA594 Phase 2a Pilot Pharmacodynamic and Safety Study
Arm 1:RDEA594 200 mg QD Screening Period Colchicine Treatment Randomize if no gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo 400 mg QD Off drug Arm 3: Allopurinol 300 mg 5 pts 5 pts 11 pts 7-21 days 1 week 2 weeks total with dose escalation of RDEA594 after Week 1 1 week Po
Slide 11: Phase 2a Cohort Baseline Demographics
Phase 2a Cohort 1 Baseline Demographics Phase 2a Cohort 1 Baseline Demographics 11
Slide 12: Both Active Arms Produced Significant Reductions in sUA
(CHART) Randomized Drug Washout Period All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers Response defined as < 6.0 mg/dL Placebo% (n/N) RDEA594% (n/N) Allopur
Slide 13: Allopurinol Results Inconsistent with Previous Studies
Allopurinol Results From RDEA594 Phase 2a Inconsistent with Previous Studies 13 Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arm from RDEA594 Phase 2a Results APEX 28-Week Study FACT 52-
Slide 14: 83% Response in Renally Impaired Patients Observed with RDEA594
(CHART) 83% Response in Renally Impaired Patients Observed with RDEA594 All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subje
Slide 15: RDEA594 Normalizes Uric Acid Excretion
RDEA594 Normalizes Uric Acid Excretion (CHART) (CHART) 15
Slide 16: RDEA594 Normalizes Uric Acid Excretion
(CHART) (CHART) RDEA594 Normalizes Uric Acid Excretion Overall results confirm dose selection for Phase 2b Keeping renal excretion of uric acid at normal levels should minimize risk of stones 16
Slide 17: Adverse Events by Treatment Group
Treatment Group Mild Moderate Severe SeriousAdverse Event Treatment Group (grade 1) (grade 2) (grade 3) SeriousAdverse Event Treatment Group N Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Numb
Slide 18: RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities
RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities Phase 2b monotherapy dose-response, safety and efficacy study (n=140) 3 doses of RDEA594 compared to placebo for 28 days of treatment Supports use in patients who are intolerant to allopurinol, inadequate responders to allopurinol
Slide 19: RDEA594 Phase 2b Monotherapy Dose-Response Study
RDEA594 Phase 2b Monotherapy Dose- Response, Safety and Efficacy Study - Enrolling 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 140 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose will
Slide 20: RDEA594 Phase 2b Allopurinol Add-On Combination Study
RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study - Enrolling Dose Escalation Based on sUA Lowering with 200 mg RDEA594: 18 patients initially, including 12 patients randomized to RDEA594 and 6 patients randomized to placebo 20 RDEA594 100 mg and 300 mg or placebo plus allopu
Slide 21: RDEA594-204: Renal Impairment in Patients with Gout
RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia - Screening Cohort 1A: (6 subjects) 200 mg RDEA594 Subjects must have moderate renal impairment defined as creatinine clearance from (CrCL) ^ 30 mL/min to < 60 mL/min. Subjects will receive RDEA594 once daily for 5 days. Cohorts 1
Slide 22: RDEA594-105: Febuxostat Drug-Drug Interaction and PD Study
RDEA594-105: Phase 1 Febuxostat Drug-Drug Interaction and PD Study - Ongoing Population: Up to 54 normal healthy volunteers with sUA ^ 6 mg/dL; 18 per panel Males and postmenopausal or sterile women 18 - 65 years of age, inclusive Up to 3 panels with escalating doses of RDEA594 or placebo - 200 mg,
Slide 23: Gout/Hyperuricemia Program Summary
23 There is a large unmet need for new treatments for gout RDEA594, a selective URAT1 transport inhibitor, corrects the physiologic cause of the vast majority of patients with hyperuricemia: uric acid under- excretion Clinical proof-of-concept has been achieved Phase 2a - Cohort 1 supports the dose
Slide 24: HIV
HIV Ardea) Biosciences
Slide 25: RDEA427 Has Superior Resistance Profile to Other NNRTIs
(CHART) RDEA427 Has Superior Resistance Profile to Other NNRTIs 25
Slide 26: Series of NNRTIs Have Excellent Antiviral Profile
900 Series of NNRTIs Have Excellent Antiviral Profile The 900 series retain potency against a large panel of NNRTI-resistant viruses without the liability of a cyano-vinyl moiety in TMC278 and IDX899 Ardea owns all the IP (CHART) 900 Series 26
Slide 27: Cancer/Inflammation
Cancer/Inflammation Ardea) Biosciences
Slide 28: The Age of Targeted Cancer Treatments
The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1/2) RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 28
Slide 29: RDEA119 is Potent, Highly Specific MEK Inhibitor
RDEA119 is Potent, Highly Specific MEK Inhibitor Inhibitor Inhibitor >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK1 & MEK2 0 20 40 60 80 100 Ron SRC RDEA
Slide 30: Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines
Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines (CHART) (CHART)
Slide 31: RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients
RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients 100 mg 60 mg 40 mg 30 mg 20 mg 10 mg 6 mg 4 mg 2 mg Shaded area represents Cmin free drug plasma levels observed in xenograft studies up to 25 mg/kg BID, which produced >100% tumor growth inhibition (TGI) QD Dose 31 Mean RDEA119
Slide 32: Phase 1/2 Advanced Cancer Sorafenib Combination Study
Study RDEA119-103 Primary Endpoint Safety and tolerability of RDEA119 in combination with sorafenib Secondary Endpoints PK, PD, efficacy Location University of Pennsylvania StudyPopulation Advanced cancer patients, all-comers until DLT reached, then expanded group of patients with specific tumors (r
Slide 33: Financial Position Summary
Financial Position Summary Statement of Operations(In thousands, except per share data) Six Months EndedJune 30, 2009 RevenueOperating expensesOther income (expense) $ 5,512 27,124 (454) NET LOSS $(22,066) NET LOSS PER SHARE $(1.23) 18.3 million common shares outstanding Expect 2009 year-end cash ba
Slide 34: Near-Term Anticipated Milestones
Near-Term Anticipated Milestones Near-Term Anticipated Milestones 34